Amplify Weight Loss Drug & Treatment ETF (NY:THNR)

26.02 +0.66 (+2.60%)

Streaming Delayed Price Updated: 3:54 PM EST, Feb 6, 2026 Add to My Watchlist

Price and Volume

Volume	16,894
Open	25.85
Bid (Size)	26.01 (900)
Ask (Size)	26.13 (100)
Prev. Close	25.36
Today's Range	25.85 - 26.02
52wk Range	18.56 - 27.28
Shares Outstanding	1,300
Dividend Yield	1.59%

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Novo Awaits FDA Call On Higher-Dose Wegovy In Early 2026 – NVO Stock Extends Decline Pre-Market On Weak Guidance ↗

February 04, 2026

Novo Nordisk submitted a supplemental New Drug Application (NDA) to the FDA in November, and under the CNPV program, a review decision is usually expected within one to two months after the filing is...

Via Stocktwits

LLY Stock Surges Pre-Market: Obesity, Diabetes Drugs Drive Strong FY26 Outlook ↗

February 04, 2026

Fourth-quarter revenue surged 43% to $19.3 billion, above Street estimates of $17.86 billion, according to Fiscal.ai data.

Via Stocktwits

Performance

YTD	+2.4%	+2.4%
1 Month	+0.8%	+0.8%
3 Month	+10.7%	+10.7%
6 Month	+18.7%	+18.7%
1 Year	+11.5%	+11.5%

More News

Regeneron’s New Growth Engine Is Starting To Show – But Core Eylea Weakness Weighs On REGN Stock ↗

January 30, 2026

Via Stocktwits

Novo Nordisk’s Worst Year In Over Four Decades May Be Ending — Thanks To A Weight-Loss Pill ↗

December 23, 2025

Via Stocktwits

The 2025 Weight-Loss Drug Gold Rush: How Eli Lilly Pulled Ahead, Novo Hit A Snag — And A Swarm Of Biotech Underdogs Are Closing In ↗

December 09, 2025

Via Stocktwits

Hims & Hers, Eli Lilly, Novo Nordisk Face FDA Scrutiny: What It Means For Weight-Loss ETFs ↗

September 18, 2025

Via Benzinga

Eli Lilly Stock Soars 34.42% YTD: A $1000 Investment Outpaces Returns From These ETFs Holding Mounjaro-Maker Shares ↗

December 13, 2024

Via Benzinga

EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players' ↗

July 18, 2024

Via Benzinga

ETFs Bet High On Weight Loss Drugs, But Industry Observers Question Long-Term Potential ↗

June 07, 2024

Via Benzinga

Frequently Asked Questions

Is Amplify Weight Loss Drug & Treatment ETF publicly traded?

Yes, Amplify Weight Loss Drug & Treatment ETF is publicly traded.

What exchange does Amplify Weight Loss Drug & Treatment ETF trade on?

Amplify Weight Loss Drug & Treatment ETF trades on the New York Stock Exchange

What is the ticker symbol for Amplify Weight Loss Drug & Treatment ETF?

The ticker symbol for Amplify Weight Loss Drug & Treatment ETF is THNR on the New York Stock Exchange

What is the current price of Amplify Weight Loss Drug & Treatment ETF?

The current price of Amplify Weight Loss Drug & Treatment ETF is 26.02

When was Amplify Weight Loss Drug & Treatment ETF last traded?

The last trade of Amplify Weight Loss Drug & Treatment ETF was at 02/06/26 03:54 PM ET

What is the market capitalization of Amplify Weight Loss Drug & Treatment ETF?

The market capitalization of Amplify Weight Loss Drug & Treatment ETF is 33.83K

How many shares of Amplify Weight Loss Drug & Treatment ETF are outstanding?

Amplify Weight Loss Drug & Treatment ETF has 34K shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.